# TRPC3 inhibition induces myofibroblast differentiation in diabetic dermal fibroblasts

## TL;DR

Blocking TRPC3 helps diabetic skin cells heal better by restoring their ability to form myofibroblasts, which are important for wound repair.

## Contribution

This study identifies TRPC3 as a novel therapeutic target for improving diabetic wound healing through its inhibition.

## Key findings

- TRPC3 inhibition restores TGF-β signaling in diabetic fibroblasts.
- TRPC3 inhibition increases expression of myofibroblast markers like ACTA2 and COL1a1.
- Elevated TRPC3 levels correlate with impaired fibroblast differentiation in diabetes.

## Abstract

Diabetic wounds present a significant healthcare challenge due to impaired healing mechanisms, with dermal fibroblasts playing a crucial role in tissue repair. This study investigates the role of transient receptor potential canonical-3 (TRPC3) in the dysfunction of diabetic fibroblasts and explores the therapeutic potential of TRPC3 inhibition. Findings reveal that TRPC3 expression is significantly elevated in diabetic dermal fibroblasts, which correlates with suppressed transforming growth factor-beta (TGF-β) signaling and impaired differentiation into myofibroblasts. Inhibiting TRPC3 effectively restores fibroblast functionality by upregulating TGF-β1 and its downstream effector, SMAD4. This restoration enhances the expression of key myofibroblast markers, such as α-smooth muscle actin (ACTA2) and type I collagen (COL1a1), which are essential for wound contraction and extracellular matrix remodeling. These results establish TRPC3 as a critical regulator of fibroblast activity and present TRPC3 inhibition as a promising therapeutic strategy for improving wound healing in diabetic patients.